戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                  It has been associated with anti-obesity actions in obese rats.
2 a and that this effect may contribute to its anti-obesity actions.
3 ensive, anti-inflammatory, antidiabetic, and anti-obesity activities.
4                   Furthermore, quercetin has anti-obesity activity through mitogen-activated protein
5 olemic, hypolipidemic, anti-atherosclerosis, anti-obesity against several disorders.
6 lly occurring adipokine, and may serve as an anti-obesity agent by upregulating the thermogenic marke
7 derma and antiprotozoal drug, is a promising anti-obesity agent in preclinical mouse and pig models.
8  previously suggested as an anorexigenic and anti-obesity agent.
9 uoromethylated analog of a hypolipidemic and anti-obesity agent.
10 ordi (thunder god vine) plant, is a powerful anti-obesity agent.
11  beta 3-selective agonists will be effective anti-obesity agents in humans is presently under investi
12 velopment of drugs that may become effective anti-obesity agents in humans.
13 hemical pathways rendering monotherapy-based anti-obesity agents relatively ineffective.
14 receptor (TR) agonists as lipid-lowering and anti-obesity agents remains largely unexplored in humans
15  are being assessed as potential therapeutic anti-obesity agents, and both potently reduce food intak
16 elopment of synthetic chromenes as potential anti-obesity agents, opening new avenues for drug discov
17 loration of synthetic chromenes as potential anti-obesity agents, unveiling the underlying molecular
18  the pursuit toward development of effective anti-obesity agents.
19 testosterone levels, and is advertised as an anti-obesity and anti-aging supplement capable of improv
20 for the development of novel antibiotics and anti-obesity and anti-cancer agents.
21 in adult humans and may be exploited for its anti-obesity and anti-diabetes actions.
22 wed interest considering the availability of anti-obesity and anti-diabetic approaches targeting GLP-
23 ne secreted by adipocytes, and known for its anti-obesity and anti-diabetic properties.
24    Inhibition of PAI-1 might provide a novel anti-obesity and anti-insulin resistance treatment.
25 ing from antidepressant and antimicrobial to anti-obesity and anticancer activity.
26 agy by disrupting the atg7 gene has a unique anti-obesity and insulin sensitization effect.
27 chondrial uncoupling with BAM15 has powerful anti-obesity and insulin sensitizing effects without com
28 important targets for the next generation of anti-obesity and metabolic therapies.
29                                          The anti-obesity and microbiota-modulating effects are trans
30 olated from the WEGL extract produce similar anti-obesity and microbiota-modulating effects.
31 ol action that extends beyond its well-known anti-obesity and mitochondrial benefits.
32 plications as being effective anti-diabetic, anti-obesity, and hypocholesterolemic agents.
33 ported for their antioxidant, anti-diabetic, anti-obesity, antihypertensive, antibacterial, antibiofi
34                                 f.) with its anti-obesity, antihypertensive, antidiabetic, and antiox
35 alls into question the potential value of an anti-obesity approach that is based on administration of
36 ism, suggesting beneficial LAL activation in anti-obesity approaches aimed at reactivating thermogeni
37 reveal the therapeutic potential of 4c as an anti-obesity candidate drug via antagonizing the H3R.
38 ch sources of polyphenols with antidiabetic, anti-obesity, cardioprotective, and anticancer potential
39 w that both hormones are necessary to elicit anti-obesity changes.
40 s what the future landscape of neurohormonal anti-obesity combinations may hold.
41 rse bioactivities, hold promise as potential anti-obesity compounds, yet research in this area remain
42                                              Anti-obesity drug development is thus focusing on target
43 ature should be considered when assessing an anti-obesity drug in mice, particularly agents acting on
44  for developing in vivo tools to move toward anti-obesity drug research focused on the Y(4)R.
45 impact of a prescan meal ("satiety") and the anti-obesity drug sibutramine, a serotonin and noradrena
46 t and has thus received much attention as an anti-obesity drug target.
47 iscrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects ac
48 s agonist a-MSH, and setmelanotide, a cyclic anti-obesity drug with biased signaling toward Gq/11, un
49 these, SR141716A was marketed as a promising anti-obesity drug, but was withdrawn from the market bec
50 ded with the following treatment categories: anti-obesity drugs (3 arms; n = 658), meal replacements
51                                   Commercial anti-obesity drugs acting in the gastrointestinal tract
52 on can be a barrier to greater acceptance of anti-obesity drugs as appropriate options for treatment.
53  of DmrB could help guide the development of anti-obesity drugs based on modification of the ecology
54 tential therapeutic target of anticancer and anti-obesity drugs by inhibiting its DNA-binding activit
55 ciated with adverse health consequences, and anti-obesity drugs can help people to lose weight, very
56                                      Several anti-obesity drugs have been approved in the USA, Europe
57                      Compared with controls, anti-obesity drugs improved weight-loss maintenance by 3
58 , and beta3-selective agonists are effective anti-obesity drugs in rodents.
59                            While in the past anti-obesity drugs offered only modest weight loss effic
60 e and remains a great unmet medical need for anti-obesity drugs that increase energy expenditure by a
61 ormation is important for the development of anti-obesity drugs that target ghrelin signaling.
62 ion in three studies, one of which also used anti-obesity drugs, and bariatric surgery in four.
63 The objective was to evaluate the effects of anti-obesity drugs, diet, or exercise on weight-loss mai
64                                              Anti-obesity drugs, meal replacements, and high-protein
65  will facilitate the development of tailored anti-obesity drugs.
66 ence, this protein is a potential target for anti-obesity drugs.
67 nor/adrenergic system is targeted by several anti-obesity drugs.
68 ral nervous system and is a prime target for anti-obesity drugs.
69 otential novel target for the development of anti-obesity drugs.
70 f FXR in the intestine could be a target for anti-obesity drugs.
71 omeostasis in humans, and offer a target for anti-obesity drugs.
72 ad to the development of systemically active anti-obesity drugs.
73 nd interleukin 1beta (IL-1beta) may exert an anti-obesity effect in the CNS during health.
74                However, no difference in the anti-obesity effect of CAP was observed at doses above 0
75 OH)2-D3-induced [Ca2+]i may contribute to an anti-obesity effect of dietary calcium, and the mVDR may
76 ptosis and thereby further contributes to an anti-obesity effect of dietary calcium.
77           Mechanistic studies indicated that anti-obesity effect of FGFR4 ASO was mediated at least i
78                                          The anti-obesity effect was accompanied by improvement in pl
79 lammatory networks, leading to a synergistic anti-obesity effect.
80 nsulin sensitization, anti-inflammatory, and anti-obesity effects and is therefore emerging as a new
81  is a leptin-sensitizing agent with profound anti-obesity effects in diet-induced obese (DIO) mice.
82 ically, BRP reduces food intake and exhibits anti-obesity effects in mice and pigs without inducing n
83  vivo mechanistic studies indicated that the anti-obesity effects of beta-LGNDs were due to indirect
84 ipocyte UCP2 expression, indicating that the anti-obesity effects of dietary calcium are mediated by
85 provide biological evidence that the pro- or anti-obesity effects of phytoestrogens are related to th
86  provide a putative mechanism to explain the anti-obesity effects of tea.
87 gesting that the intestinal FXR mediates the anti-obesity effects of tempol.
88  administration of IL-33 results in multiple anti-obesity effects, including the reversal of VAT infl
89 sveratrol (REV) is a natural polyphenol with anti-obesity effects.
90 onselective, Amy-based DACRAs with potential anti-obesity effects.
91  manipulated, had pronounced pro-obesity and anti-obesity effects.
92 y of first-order neurons initiating leptin's anti-obesity effects.
93 erosclerosis, anti-aging, anti-osteoporosis, anti-obesity, estrogenic, neuroprotective and cardioprot
94 les with adipocyte-specific knockdown of the anti-obesity genes brummer or adipose are obese but have
95 osed that leptin serves a primary role as an anti-obesity hormone, but this role is commonly thwarted
96 and their subsequent bioactivities including anti-obesity, immunomodulatory, antioxidant, angiotensin
97 ograms, and is a highly promising target for anti-obesity immunotherapy.
98 des, which reveals their potential to act as anti-obesity ingredients.
99 GF21 is a stress-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective
100  therapy in patients with cardiomyopathy and anti-obesity interventions for patients with heart failu
101 This BHB shunt pathway generates a family of anti-obesity ketone metabolites, the BHB-amino acids.
102  a metabolomics-driven effort to uncover the anti-obesity mechanism(s) of xanthohumol (XN), a prenyla
103 h HGD and HBD groups, implying the different anti-obesity mechanisms.
104 as important health-related implications for anti-obesity medical therapy and lipodystrophy.
105                                          The anti-obesity medication rimonabant, an antagonist of can
106 ity includes lifestyle modification therapy, anti-obesity medications (AOMs) and/or metabolic surgery
107                                              Anti-obesity medications (AOMs) are recommended when tar
108 as proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insuffi
109 d potential alternatives, currently approved anti-obesity medications and best practices to individua
110 gation, summarize the next phase of emerging anti-obesity medications and provide practical clinical
111 ticularly HFrEF; and whether the benefits of anti-obesity medications are attributed mainly to the ma
112                       Although few promising anti-obesity medications are in the drug-development pip
113 i-obesity medications; the safety profile of anti-obesity medications for individuals with HF, partic
114  has made it possible to study the impact of anti-obesity medications for patients with baseline card
115                 Despite the early promise of anti-obesity medications in HFpEF, challenges remain, in
116 we show that semaglutide compared with other anti-obesity medications is associated with a 50%-56% lo
117 ts will likely herald a second generation of anti-obesity medications over the next decade.
118 omen), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk
119  semaglutide compared with non-GLP1R agonist anti-obesity medications was associated with lower risk
120                             The emergence of anti-obesity medications with cardiovascular outcomes be
121 tyle changes, interventional procedures, and anti-obesity medications with particular focus on their
122  options, such as lifestyle modification and anti-obesity medications, often exhibit limited efficacy
123  prescribed semaglutide or non-GLP1R agonist anti-obesity medications, with the findings replicated i
124 o were prescribed semaglutide or non-GLP-1RA anti-obesity medications, with the findings replicated i
125 refore, hold great promise for the future of anti-obesity medications.
126 hat inactivate perilipin may prove useful as anti-obesity medications.
127 identify obesity and subsequent benefit from anti-obesity medications; the safety profile of anti-obe
128 ated protein (FTO) is a potential target for anti-obesity medicines.
129 inflammatory, antioxidant, immunomodulatory, anti-obesity, neuroprotective, antidiabetic, hepatoprote
130 urrent CUD diagnosis compared to non-GLP-1RA anti-obesity or anti-diabetes medications.
131 cidal ideation compared to non-GLP1R agonist anti-obesity or anti-diabetes medications.
132  semaglutide compared with non-GLP1R agonist anti-obesity or anti-diabetes medications.
133 ects of developing long- to ultralong-acting anti-obesity peptides.
134 cantly higher antioxidant, anti-diabetic and anti-obesity properties than snacks containing no or fre
135 polysis, providing further evidence of their anti-obesity properties.
136 kkermansia muciniphila, a bacterium with the anti-obesity property.
137 ulation of satiety, offer great potential in anti-obesity research.
138  cleaving an anorexigenic receptor may be an anti-obesity strategy.
139              DGAT1 has been recognized as an anti-obesity target; however, its role in the tumor micr
140                       We highlight potential anti-obesity therapeutic approaches that emerge from the
141 otential, efforts to develop an amylin-based anti-obesity therapeutic stalled owing to challenges aro
142 yte development inhibitors could be a viable anti-obesity therapeutic.
143  carboxylase may be a suitable target for an anti-obesity therapeutic.
144 s but also presents a probable candidate for anti-obesity therapeutics.
145 targeted enzyme inhibitors have potential as anti-obesity therapeutics.
146 ary neurotrophic factor (CNTF), as potential anti-obesity therapeutics.
147                                   Generally, anti-obesity therapies have displayed modest efficacy an
148 l approaches targeting IRS4(PVH) neurons for anti-obesity therapies.
149 ity of BAT makes it an attractive target for anti-obesity therapies.
150 ilities for future development of successful anti-obesity therapies.
151 w evaluates current and future pharmacologic anti-obesity therapy in adults through a kidney-oriented
152                It also explores the goals of anti-obesity treatment, describes the underlying putativ
153 2 diabetes, and was also explored as a novel anti-obesity treatment.
154 of body weight and hold potential as a novel anti-obesity treatment.
155                                              Anti-obesity treatments including diet, exercise, surger
156 erapeutic potential and developing effective anti-obesity treatments.
157 may prove to be effective and more selective anti-obesity treatments.

 
Page Top